Diasome Pharmaceuticals, Inc.
CLEVELAND, OH · Founded 2008 · CIK 0001411617 · Biotech · Private
HDV™ platform for liver-targeted drug delivery
diasome.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $50M
- 7 Form D · Aug 2024
- 26 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 0 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $4,350,000 | |
| Private capital raised | Form D · SEC | $12,084,000 | |
| Private capital raised | Form D · SEC | $2,885,788 | |
| Private capital raised | Form D · SEC | $1,500,000 | |
| Private capital raised | Form D · SEC | $16,724,591 | |
| Private capital raised | Form D · SEC | $8,999,998 | |
| Private capital raised | Form D · SEC | $3,090,740 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2952 | PLUMB PHARMACEUTICALS, INC | — | — |
| 2953 | Stem Cell Development Fund, LLC | — | $2.8M |
| 2954 | TISSUEFORM, INC. | — | — |
| 2955 | Diasome Pharmaceuticals, Inc. | — | $50M |
| 2956 | ONCOCEUTICS, INC. | — | — |
| 2957 | INTEGRATED ANIMAL RESEARCH LLC | — | — |
| 2958 | TEZCAT Laboratories LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Richard CarusoDirector
- Brenda GavinDirector
- Robert GehoDirector · Executive Officer · Promoter
- W. GehoDirector · Executive Officer
- W. Blair GehoDirector
- Devang KantesariaDirector
- Helga KautskyExecutive Officer
- Frank McCaneyDirector
- Thomas McDonaldDirector
- Michele OllierDirector
- Cosme OrdonezDirector
- Marc PennDirector
- Len RosenbergDirector · Executive Officer
- Peter TollmanDirector
- Guiseppe ZoccoDirector
Patents
- Orally Bioavailable Lipid-based Constructsapplication
- Lipid Construct For Delivery Of Insulin To A Mammalapplication
- Orally Bioavailable Lipid-based Constructsapplication
- Lipid Construct For Delivery Of Insulin To A Mammalapplication
- Orally Bioavailable Lipid-based Constructsapplication
- Orally Bioavailable Lipid-based Constructsapplication
- Lipid Construct For Delivery Of Insulin To A Mammalapplication
- Incretin Hormone Compositions And Methods Using Sameapplication
- Incretin Hormone Compositions And Methods Using Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.